Skip to content

How much of the poor-quality oxytocin (the main drug to prevent heavy bleeding after birth) found in low- and middle-income countries is explained by the heat it meets between the factory and the delivery room, and in which places and seasons is it likely to have lost potency by the time it is used?

Good it would do
4 / 5
Can AI help
2 / 5
How neglected
3 / 5
Can we check it
2 / 5

Why it's stuck

A 2020 review of oxytocin quality (Lambert et al., PMC7227300) reports that a systematic review by Torloni and colleagues found unacceptable oxytocin content in 36% of 559 samples from 15 low- and middle-income countries (the samples were not random), that 'cumulative heat exposure is generally not tracked and leads to degradation', that 'there is no test to assess oxytocin content of the injection products at lower levels of the health system', and that heat-stable carbetocin was not yet available in most of these countries. So nobody knows, place by place, whether bad oxytocin comes from heat on the way or from poor manufacturing, which call for different fixes.

What we'd try

Hawe et al. (Pharmaceutical Research 2009;26:1679) measured oxytocin breakdown at 40 to 80 °C and four acidity levels and found it follows first-order kinetics described by the Arrhenius equation (activation energy 116.3 kJ/mol at pH 4.5).

What could stop us

The field quality surveys are small and not random, and breakdown rates measured at 40 C and above must be extrapolated to 25-35 C, so the heat-versus-manufacturing split may stay inconclusive.

Source: https://pmc.ncbi.nlm.nih.gov/articles/PMC7227300

Do you know the answer?

One reply from someone in the field can settle what our AI can't.

Members can read the full record for this problem, check its sources and comment. Open the member view →